8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Feb 26, 2026·SEC
Caris Life Sciences, Inc.(CAI)Earnings, Financials & Key Ratios
CAI•NASDAQ
Price updated Jun 17, 2026
AboutCaris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.Show more
- Revenue$812M+97.0%
- EBITDA$68M+132.5%
- Net Income-$538M-90.8%
- EPS (Diluted)-1.90+29.6%
- Gross Margin66.4%+53.1%
- EBITDA Margin8.34%+116.5%
- Operating Margin5.56%+108.9%
- Net Margin-66.25%+3.1%
- ROE-93.18%
CAI Key Insights
Caris Life Sciences, Inc. (CAI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 14.3%
✗Weaknesses
- ✗Weak momentum: RS Rating 20 (bottom 20%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 51.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CAI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CAI Price & Volume
Caris Life Sciences, Inc. (CAI) stock price & volume — 10-year historical chart
Loading chart...
CAI Growth Metrics
Caris Life Sciences, Inc. (CAI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years13.56%
5 Years14.28%
3 Years46.46%
TTM133.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM52.68%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-122.43%
Return on Capital
10 Years-15.93%
5 Years-36.69%
3 Years-55.71%
Last Year7.67%
CAI Recent Earnings
Caris Life Sciences, Inc. (CAI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/4 qtrs (75%)●Beat Revenue 3/4 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.00+92.5%
$0.02
Rev
$216M+3.2%
$209M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.28+1500.0%
$0.02
Rev
$293M+21.8%
$240M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.08+200.0%
$0.08
Rev
$217M-22.8%
$281M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.54-157.1%
$0.21
Rev
$181M+31.8%
$138M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.00vs $0.02+92.5% | $216Mvs $209M+3.2% |
| Q1 2026 | Feb 26, 2026 | $0.28vs $0.02+1500.0% | $293Mvs $240M+21.8% |
| Q4 2025 | Nov 5, 2025 | $0.08vs $0.08+200.0% | $217Mvs $281M-22.8% |
| Q3 2025 | Aug 12, 2025 | $0.54vs $0.21-157.1% | $181Mvs $138M+31.8% |
Based on last 4 quarters of dataView full earnings history →
CAI Peer Comparison
Caris Life Sciences, Inc. (CAI) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 ILMN | 24.17B | 159.09 | 29.19 | -0.78% | 19.43% | 32.84% | 0.94 | |
 NTRA | 32.43B | 226.44 | -148.97 | 35.9% | -9.05% | -15.13% | 0.13 | |
 GH | 17.12B | 129.11 | -38.89 | 32.88% | -40.1% | |||
 FDMT | 492.43M | 9.42 | -3.89 | 2301.95% | -182.34% | -36.83% | 0.04 | |
 CDNA | 1.21B | 23.48 | -58.70 | 13.79% | -1.98% | -2.61% | 0.06 | |
 PACB | 416.21M | 1.34 | -0.74 | 3.89% | -80.34% | -488.45% | 141.98 | |
 CERT | 938.05M | 6.03 | -603 | 8.75% | -3.6% | -1.43% | 0.01 |
Compare CAI vs Peers
Caris Life Sciences, Inc. (CAI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CAI Income Statement
Caris Life Sciences, Inc. (CAI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 294.35M | 348.39M | 432.1M | 416.54M | 294.01M | 258.49M | 306.13M | 412.26M | 812.03M | 907.29M |
Revenue Growth % | 17.9% | 18.36% | 24.03% | -3.6% | -29.42% | -12.08% | 18.43% | 34.67% | 96.97% | 133.7% |
Cost of Goods Sold | 156.86M | 179.11M | 218.47M | 216.03M | 109.86M | 178.46M | 216.82M | 233.48M | 272.87M | 283.84M |
COGS % of Revenue | 53.29% | 51.41% | 50.56% | 51.86% | 37.36% | 69.04% | 70.83% | 56.63% | 33.6% | - |
Gross Profit | 137.5M▲ 0% | 169.29M▲ 23.1% | 213.63M▲ 26.2% | 200.51M▼ 6.1% | 184.16M▼ 8.2% | 80.02M▼ 56.5% | 89.31M▲ 11.6% | 178.78M▲ 100.2% | 539.17M▲ 201.6% | 623.45M▲ 0% |
Gross Margin % | 46.71% | 48.59% | 49.44% | 48.14% | 62.64% | 30.96% | 29.17% | 43.37% | 66.4% | 68.72% |
Gross Profit Growth % | 9.21% | 23.12% | 26.19% | -6.14% | -8.16% | -56.55% | 11.61% | 100.18% | 201.58% | - |
Operating Expenses | 71.54M | 63.62M | 64.85M | 70.23M | 45.07M | 395.78M | 408.86M | 435.9M | 494.06M | 479.13M |
OpEx % of Revenue | 24.3% | 18.26% | 15.01% | 16.86% | 15.33% | 153.11% | 133.56% | 105.74% | 60.84% | - |
Selling, General & Admin | 35.68M | 42.7M | 50.3M | 52.7M | 27.31M | 294.51M | 291.48M | 321.86M | 392.47M | 405.28M |
SG&A % of Revenue | 12.12% | 12.26% | 11.64% | 12.65% | 9.29% | 113.94% | 95.21% | 78.07% | 48.33% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 101.27M | 116.88M | 113.92M | 45.31M | 83.89M |
R&D % of Revenue | - | - | - | - | - | 39.18% | 38.18% | 27.63% | 5.58% | - |
Other Operating Expenses | 35.86M | 20.92M | 14.54M | 17.53M | 17.76M | 0 | 500K | 128K | 56.27M | 0 |
Operating Income | 65.96M▲ 0% | 105.67M▲ 60.2% | 148.78M▲ 40.8% | 130.28M▼ 12.4% | 139.09M▲ 6.8% | -315.76M▼ 327.0% | -319.55M▼ 1.2% | -257.12M▲ 19.5% | 45.11M▲ 117.5% | 144.32M▲ 0% |
Operating Margin % | 22.41% | 30.33% | 34.43% | 31.28% | 47.31% | -122.16% | -104.38% | -62.37% | 5.56% | 15.91% |
Operating Income Growth % | -3.14% | 60.21% | 40.8% | -12.43% | 6.76% | -327.02% | -1.2% | 19.54% | 117.55% | - |
EBITDA | 172.64M | 218.93M | 272.26M | 244.21M | 249.74M | -267.5M | -270.55M | -208.21M | 67.73M | 164.96M |
EBITDA Margin % | 58.65% | 62.84% | 63.01% | 58.63% | 84.94% | -103.49% | -88.38% | -50.5% | 8.34% | 18.18% |
EBITDA Growth % | -5.32% | 26.82% | 24.36% | -10.3% | 2.26% | -207.11% | -1.14% | 23.04% | 132.53% | -20.02% |
D&A (Non-Cash Add-back) | 106.68M | 113.26M | 123.48M | 113.93M | 110.65M | 48.25M | 49M | 48.91M | 22.61M | 20.64M |
EBIT | 52.63M | 110.25M | 159.83M | 134.37M | 143.81M | -294.15M | -309.81M | -231.87M | -11.23M | 83.84M |
Net Interest Income | 0 | 0 | 0 | -79.16M | -61.56M | -25.73M | -20.35M | -42.9M | -40.36M | -34.05M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 947K | 11.26M | 7.12M | 16.5M | 22.83M |
Interest Expense | 42.75M | 53.05M | 78.34M | 79.16M | 61.56M | 26.68M | 31.61M | 50.02M | 56.85M | 56.88M |
Other Income/Expense | -56.08M | -48.47M | -67.3M | 0 | -109.55M | -5.07M | -21.86M | -24.77M | -113.2M | -110.48M |
Pretax Income | 9.88M▲ 0% | 57.2M▲ 479.1% | 81.48M▲ 42.5% | 55.21M▼ 32.2% | 29.53M▼ 46.5% | -320.83M▼ 1186.3% | -341.42M▼ 6.4% | -281.89M▲ 17.4% | -68.09M▲ 75.8% | 33.85M▲ 0% |
Pretax Margin % | 3.36% | 16.42% | 18.86% | 13.26% | 10.04% | -124.12% | -111.53% | -68.38% | -8.38% | 3.73% |
Income Tax | 3.84M | -14.86M | 2.89M | 4.19M | 1.8M | 0 | 0 | 0 | 469.87M | -134K |
Effective Tax Rate % | 38.91% | -25.98% | 3.54% | 7.59% | 6.09% | 0% | 0% | 0% | -690.09% | -0.4% |
Net Income | 6M▲ 0% | 72.06M▲ 1101.6% | 78.6M▲ 9.1% | 31.01M▼ 60.5% | 27.73M▼ 10.6% | -320.83M▼ 1256.8% | -341.42M▼ 6.4% | -281.89M▲ 17.4% | -537.96M▼ 90.8% | 33.98M▲ 0% |
Net Margin % | 2.04% | 20.68% | 18.19% | 7.44% | 9.43% | -124.12% | -111.53% | -68.38% | -66.25% | 3.75% |
Net Income Growth % | -77.65% | 1101.6% | 9.07% | -60.54% | -10.57% | -1256.84% | -6.42% | 17.43% | -90.84% | 52.68% |
Net Income (Continuing) | 6M | 72.06M | 78.6M | 31.01M | 27.73M | -320.83M | -341.42M | -281.89M | -537.96M | 33.98M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.31▲ 0% | 3.68▲ 1087.1% | 3.97▲ 7.9% | 1.72▼ 56.7% | 1.55▼ 9.9% | -1.57▼ 201.3% | -1.82▼ 15.9% | -2.70▼ 48.4% | -1.90▲ 29.6% | 0.12▲ 0% |
EPS Growth % | -75.78% | 1087.1% | 7.88% | -56.68% | -9.88% | -201.29% | -15.92% | -48.35% | 29.63% | -122.43% |
EPS (Basic) | 0.31 | 3.74 | 3.97 | 1.72 | 1.55 | -1.57 | -1.82 | -2.70 | -1.90 | - |
Diluted Shares Outstanding | 19.39M | 19.61M | 19.82M | 18.01M | 17.95M | 254.79M | 254.66M | 254.66M | 1.67B | 282.56M |
Basic Shares Outstanding | 19.32M | 19.25M | 19.82M | 18.01M | 17.95M | 254.79M | 254.66M | 254.66M | 1.67B | 282.56M |
Dividend Payout Ratio | - | - | 4.15% | 28.47% | 63.84% | - | - | - | - | - |
CAI Balance Sheet
Caris Life Sciences, Inc. (CAI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 135.15M | 140.34M | 220.02M | 499.13M | 214.66M | 516.04M | 242.61M | 215.73M | 997.8M | 1.01B |
Cash & Short-Term Investments | 66.09M | 65.48M | 121.29M | 46.46M | 132.54M | 409.62M | 121.59M | 66.15M | 800.09M | 823.46M |
Cash Only | 46.13M | 35.42M | 45.31M | 46.46M | 53.55M | 107.19M | 56.4M | 63.95M | 797.8M | 821.15M |
Short-Term Investments | 19.96M | 30.06M | 75.97M | 0 | 78.99M | 302.43M | 65.18M | 2.2M | 2.29M | 2.31M |
Accounts Receivable | 83.7M | 100.66M | 171.92M | 159.68M | 144.3M | 40.23M | 55.3M | 88.24M | 112.14M | 90.52M |
Days Sales Outstanding | 103.79 | 105.46 | 145.22 | 139.92 | 179.14 | 56.8 | 65.93 | 78.13 | 50.41 | 28.19 |
Inventory | 0 | 0 | 0 | 0 | 0 | 46.96M | 49M | 39.57M | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | 96.04 | 82.49 | 61.86 | - | 28.91 |
Other Current Assets | -14.64M | -25.8M | -73.19M | 292.98M | -62.18M | 5.88M | 4.96M | 8.2M | 85.57M | 100.2M |
Total Non-Current Assets | 1.92B | 2.29B | 2.79B | 2.4B | 2.4B | 201.38M | 170.29M | 128M | 127.86M | 148.21M |
Property, Plant & Equipment | 1.81B | 2.01B | 2.27B | 1.82B | 1.78B | 138.05M | 147.51M | 102.77M | 63.17M | 82.67M |
Fixed Asset Turnover | 0.16x | 0.17x | 0.19x | 0.23x | 0.17x | 1.87x | 2.08x | 4.01x | 12.85x | 13.38x |
Goodwill | 15.79M | 15.79M | 15.79M | 15.79M | 0 | 19.34M | 19.34M | 19.34M | 19.34M | 19.34M |
Intangible Assets | 9.69M | 7.72M | 5.73M | 4.12M | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 80.58M | 246.45M | 473.79M | 495.49M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 7.15M | 14.8M | 31.05M | 66.5M | 616.65M | 43.98M | 3.43M | 5.89M | 45.35M | 46.2M |
Total Assets | 2.06B▲ 0% | 2.43B▲ 18.2% | 3.01B▲ 24.0% | 2.9B▼ 3.7% | 2.61B▼ 10.0% | 717.42M▼ 72.5% | 412.9M▼ 42.4% | 343.73M▼ 16.8% | 1.13B▲ 227.5% | 1.16B▲ 0% |
Asset Turnover | 0.14x | 0.14x | 0.14x | 0.14x | 0.11x | 0.36x | 0.74x | 1.20x | 0.72x | 0.86x |
Asset Growth % | 3.49% | 18.21% | 23.96% | -3.68% | -9.96% | -72.54% | -42.45% | -16.75% | 227.48% | 298.65% |
Total Current Liabilities | 164.01M | 259.93M | 425.53M | 287.41M | 320.25M | 136.91M | 95.14M | 165.42M | 127.14M | 143.9M |
Accounts Payable | 13.8M | 7.83M | 7.37M | 7.29M | 3.67M | 27.27M | 26.68M | 27.79M | 39.21M | 69.8M |
Days Payables Outstanding | 32.12 | 15.96 | 12.31 | 12.32 | 12.18 | 55.77 | 44.91 | 43.45 | 52.44 | 53.6 |
Short-Term Debt | 95.53M | 132.05M | 311.38M | 218.09M | 183.45M | 52.79M | 167K | 60M | 169K | 173K |
Deferred Revenue (Current) | 10.61M | 7.81M | 7.57M | 6.41M | 3.03M | 1.43M | 5.68M | 7.47M | 0 | 5.34M |
Other Current Liabilities | 44.06M | 112.24M | 99.21M | 55.62M | 130.11M | 22.65M | 22.13M | 30.69M | 87.77M | 73.92M |
Current Ratio | 0.82x | 0.54x | 0.52x | 1.74x | 0.67x | 3.77x | 2.55x | 1.30x | 7.85x | 7.05x |
Quick Ratio | 0.82x | 0.54x | 0.52x | 1.74x | 0.67x | 3.43x | 2.04x | 1.06x | 7.85x | 7.05x |
Cash Conversion Cycle | - | - | - | - | - | 97.07 | 103.5 | 96.55 | - | 3.49 |
Total Non-Current Liabilities | 1.43B | 1.61B | 1.89B | 1.92B | 1.59B | 2.28B | 2.46B | 2.68B | 421.21M | 425M |
Long-Term Debt | 1.38B | 1.57B | 1.85B | 1.88B | 1.56B | 169.57M | 166.11M | 319.19M | 378.82M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 44.2M | 44.41M | 38.89M | 0 | 81.81M |
Deferred Tax Liabilities | 51.8M | 35.85M | 38.32M | 35.38M | 24.44M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2.12M | 0 | 0 | 5.62M | 3.42M | 2.07B | 2.25B | 2.32B | 42.39M | 425M |
Total Liabilities | 1.6B | 1.87B | 2.31B | 2.21B | 1.91B | 2.42B | 2.56B | 2.84B | 548.36M | 568.9M |
Total Debt | 1.48B | 1.7B | 2.16B | 2.1B | 1.75B | 270.87M | 217.27M | 424.26M | 378.99M | 173K |
Net Debt | 1.43B | 1.67B | 2.11B | 2.05B | 1.69B | 163.68M | 160.87M | 360.31M | -418.81M | -820.97M |
Debt / Equity | 3.23x | 3.02x | 3.08x | 3.03x | 2.49x | - | - | - | 0.66x | 0.00x |
Debt / EBITDA | 8.55x | 7.78x | 7.93x | 8.59x | 6.99x | - | - | - | 5.60x | 0.00x |
Net Debt / EBITDA | 8.28x | 7.62x | 7.76x | 8.40x | 6.78x | - | - | - | -6.18x | -4.98x |
Interest Coverage | 1.23x | 2.08x | 2.04x | 1.70x | 2.34x | -11.03x | -9.80x | -4.63x | -0.20x | 1.47x |
Total Equity | 457.5M▲ 0% | 563.85M▲ 23.2% | 701.13M▲ 24.3% | 693.24M▼ 1.1% | 702.24M▲ 1.3% | -1.7B▼ 342.4% | -2.14B▼ 26.0% | -2.5B▼ 16.5% | 577.31M▲ 123.1% | 593.49M▲ 0% |
Equity Growth % | - | 23.24% | 24.35% | -1.13% | 1.3% | -342.38% | -26.02% | -16.5% | 123.1% | 122.83% |
Book Value per Share | 23.59 | 28.76 | 35.38 | 38.49 | 39.12 | -6.68 | -8.42 | -9.81 | 0.35 | 2.10 |
Total Shareholders' Equity | 457.5M | 563.85M | 701.13M | 693.24M | 702.24M | -1.7B | -2.14B | -2.5B | 577.31M | 593.49M |
Common Stock | 2K | 2K | 2K | 2K | 2K | 138K | 38K | 38K | 283K | 284K |
Retained Earnings | 324.58M | 397.64M | 471.11M | 493.29M | 503.32M | -1.68B | -2.12B | -2.47B | -2.55B | -2.55B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -330K | -330K | -330K | -16.9M | 0 |
Accumulated OCI | -8.13M | -6.12M | -6.51M | -6.63M | -5.74M | 1.7M | 218K | 210K | 936K | 893K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CAI Cash Flow Statement
Caris Life Sciences, Inc. (CAI) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 129.26M | 155.19M | 179.77M | 254M | 277.02M | -285.71M | -276.1M | -245.2M | 83.16M | 147.37M |
Operating CF Margin % | 43.91% | 44.55% | 41.6% | 60.98% | 94.22% | -110.53% | -90.19% | -59.48% | 10.24% | - |
Operating CF Growth % | -12.29% | 20.07% | 15.84% | 41.29% | 9.06% | -203.14% | 3.36% | 11.19% | 133.91% | 204.91% |
Net Income | 6M | 72.06M | 78.6M | 31.01M | 27.73M | -320.83M | -341.42M | -281.89M | -68.09M | 33.98M |
Depreciation & Amortization | 106.68M | 113.26M | 123.48M | 113.93M | 110.65M | 48.25M | 49M | 48.91M | 22.61M | 23.1M |
Stock-Based Compensation | 1.73M | 2.09M | 2.87M | 2.76M | 1.77M | 22.9M | 15.24M | 18.64M | 70.01M | 55.31M |
Deferred Taxes | 1.14M | -14.95M | 2.47M | 3.73M | 1.37M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -31.21M | 73.47M | 58.28M | -314.67M | 452.8M | -13.78M | 8.2M | -1.8M | 91.75M | 73.86M |
Working Capital Changes | 44.92M | -90.74M | -85.92M | 417.23M | -317.31M | -22.26M | -7.13M | -29.07M | -33.13M | -38.89M |
Change in Receivables | -1.8M | -7.8M | -19.27M | 3.86M | 11M | -11.9M | -15.08M | -33.82M | -29.79M | -16.08M |
Change in Inventory | 72M | 38.86M | 138.85M | 0 | 0 | -11.1M | -4.43M | 5.46M | -20.75M | -36.14M |
Change in Payables | 3.57M | -2.21M | 15K | 0 | 0 | 8.91M | 7.17M | -226K | 11.04M | 28.42M |
Cash from Investing | -181.6M | -411.75M | -663.34M | -271.87M | -33.97M | -282.99M | 214.77M | 52.93M | -16.26M | -23.91M |
Capital Expenditures | -251.25M | -502.18M | -812.84M | -319.14M | -219.45M | -42.26M | -22.32M | -8.44M | -16.26M | -23.91M |
CapEx % of Revenue | 85.36% | 144.14% | 188.12% | 76.62% | 74.64% | 16.35% | 7.29% | 2.05% | 2% | 2.64% |
Acquisitions | -16.06M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 66.07M | 66.36M | 106.15M | 47.27M | 185.48M | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 46.6M | 245.63M | 512.35M | -108.48M | -249.88M | 10.45M | 10.13M | 200.29M | 664.99M | 664.53M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -962K | 10.57M | 199.82M | 16.05M | 27.74M |
Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 667.49M | -409K |
Dividends Paid | 0 | 0 | -3.26M | -8.83M | -17.71M | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -9.18M | 0 | -40.87M | -34.12M | -7.95M | 0 | 0 | 0 | -113K | -16.65M |
Other Financing | 46.6M | 245.63M | 515.61M | -99.65M | -232.18M | 11.41M | -435K | 471K | -18.55M | 637.2M |
Net Change in Cash | -6.42M▲ 0% | -10.71M▼ 66.9% | 28.77M▲ 368.6% | -2.74M▼ 109.5% | -6.74M▼ 145.5% | -558.25M▼ 8186.3% | -51.13M▲ 90.8% | 8.02M▲ 115.7% | 732.01M▲ 9026.2% | 788.1M▲ 0% |
Free Cash Flow | -121.99M▲ 0% | -346.98M▼ 184.4% | -633.07M▼ 82.5% | -65.14M▲ 89.7% | 57.57M▲ 188.4% | -327.96M▼ 669.7% | -298.42M▲ 9.0% | -253.64M▲ 15.0% | 66.89M▲ 126.4% | 123.46M▲ 0% |
FCF Margin % | -41.44% | -99.6% | -146.51% | -15.64% | 19.58% | -126.88% | -97.48% | -61.52% | 8.24% | 13.61% |
FCF Growth % | 49.6% | -184.43% | -82.45% | 89.71% | 188.37% | -669.71% | 9.01% | 15% | 126.37% | 120.71% |
FCF per Share | -6.29 | -17.70 | -31.94 | -3.62 | 3.21 | -1.29 | -1.17 | -1.00 | 0.04 | 0.44 |
FCF Conversion (FCF/Net Income) | 21.55x | 2.15x | 2.29x | 8.19x | 9.99x | 0.89x | 0.81x | 0.87x | -0.15x | 3.63x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 24.24M | 15.78M | 49.02M | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CAI Key Ratios
Caris Life Sciences, Inc. (CAI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 1.31% | 14.11% | 12.43% | 4.45% | 3.97% | - | - | - | -93.18% | 6.47% |
Return on Invested Capital (ROIC) | 2.65% | 3.85% | 4.42% | 3.51% | 4.06% | -55.33% | - | - | 21.35% | 183.58% |
Gross Margin | 46.71% | 48.59% | 49.44% | 48.14% | 62.64% | 30.96% | 29.17% | 43.37% | 66.4% | 68.72% |
Net Margin | 2.04% | 20.68% | 18.19% | 7.44% | 9.43% | -124.12% | -111.53% | -68.38% | -66.25% | 3.75% |
Debt / Equity | 3.23x | 3.02x | 3.08x | 3.03x | 2.49x | - | - | - | 0.66x | 0.00x |
Interest Coverage | 1.23x | 2.08x | 2.04x | 1.70x | 2.34x | -11.03x | -9.80x | -4.63x | -0.20x | 1.47x |
FCF Conversion | 21.55x | 2.15x | 2.29x | 8.19x | 9.99x | 0.89x | 0.81x | 0.87x | -0.15x | 3.63x |
Revenue Growth | 17.9% | 18.36% | 24.03% | -3.6% | -29.42% | -12.08% | 18.43% | 34.67% | 96.97% | 133.7% |
Related:CAI Dividend History·CAI Revenue History·CAI Price History·CAI P/E History·CAI Financial Ratios·CAI Institutional Holders
CAI SEC Filings & Documents
Caris Life Sciences, Inc. (CAI) SEC filings — annual & quarterly reports (10-K, 10-Q)
CAI Frequently Asked Questions
Caris Life Sciences, Inc. (CAI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Caris Life Sciences, Inc. (CAI) reported $907.3M in revenue for fiscal year 2025. This represents a 1787% increase from $48.1M in 2003.
Caris Life Sciences, Inc. (CAI) grew revenue by 97.0% over the past year. This is strong growth.
Yes, Caris Life Sciences, Inc. (CAI) is profitable, generating $34.0M in net income for fiscal year 2025 (-66.2% net margin).
Dividend & Returns
Caris Life Sciences, Inc. (CAI) has a return on equity (ROE) of -93.2%. Negative ROE indicates the company is unprofitable.
Caris Life Sciences, Inc. (CAI) generated $123.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.